Delivering specialty solutions with a patient-centered approach
“I was holding a vial in my hand worth more than $3,000.”
December 27, 2018
HAE is a rare, genetic condition that affects less than 400 of Prime’s 27 million members. Yet Prime’s clients spent $92.3 million on HAE treatment in 2017.
“I was a student on rotation at Children’s Hospital in St. Paul the first time I came across a patient with hereditary angioedema,” Sara said. “The patient’s parents brought the acute attack drug with them. Not only do these patients and families deal with a disease that can be life-threatening, they have to keep their medications with them at all times for situations like these.”
In 2015, Sara was in her third year in pharmacy school. Representatives from Prime came to one of her classes and did a presentation on research, formulary development and managed care pharmacy.
“I was hooked,” Sara says. She signed up for a five-week rotation at Prime. Then Sara was accepted into Prime’s one-year residency program, which rotated her through ten different departments. “I was lucky to have wonderful mentors during my residency. They supported me and challenged me to expand my skillset. I interacted with a lot of dynamic teams within Prime,” remembers Sara.
During Sara’s residency, she worked with Prime’s health outcomes team on a cost of care study on HAE. “I learned that most of our competitors are not looking at drug spend across both the medical and pharmacy benefits like we are,” she said.
Bringing the research to clients
In March 2018, Sara presented Prime’s integrated medical and pharmacy research on HAE to Blue Cross and Blue Shield medical and pharmacy directors.
“I think I was more excited than nervous,” Sara says. “This was research that Prime’s clients were really interested in. The audience was very receptive. More important, the discussion after the presentation added a lot of value.”
Some Blue Plans presented challenges and successes they have had with programs supporting members with HAE. Blue Cross & Blue Shield of Rhode Island has an embedded pharmacist program that has had success with one-on-one pharmacist case management.
In mid-2018, Sara stepped from the residency into an open position as Prime’s specialty clinical program pharmacist for HAE.
Research findings: outliers; new starts; key drugs
HAE is a complex and challenging condition to treat. It includes episodes of acute, potentially life-threatening swelling in different parts of the body.
- ~50 percent of drug spend is under the pharmacy benefit and ~50 percent of drug spend is under the medical benefit
23 percent of members were new starts in the study period
9 percent (outliers within the HAE group) had more than $1 million in HAE drug spend, accounting for 30 percent of Prime’s overall HAE spend
Cinryze® and Firazyr®, injectable specialty drugs, make up 87 percent of HAE drug spend
Many Blue Plans considering pharmacist care
Prime’s recommendation for improving health outcomes and controlling costs is a high-touch pharmacist care program, assigned at the first fill of one of the HAE drugs. Prime presented an example of how pharmacist case management can work.
- 62-year-old female
- Concurrent use of two acute HAE medications
- Drug 1: $694,909 billed on medical benefit
- Drug 2: $618,220 billed on pharmacy benefit
- No prophylactic HAE medications
- 30 hospital/ER visits in one year
Prime’s proposed interventions
- Limited use to one acute medication and started prophylactic medication to reduce number of attacks
- Helped identify triggers for attacks including environmental triggers, stress, medications, etc.
- Referred member to specialist and recommended mental health consultation
Prime case management could potentially reduce cost by 25 percent
A pharmacist care program that validates diagnosis (medical claims), confirms dosage and helps the member manage the use of multiple drugs could potentially save plans up to 25 percent of their HAE drug costs per year.
Looking at the whole patient
Producing groundbreaking research. Inspiring future leaders in managed care pharmacy. Fostering collaborative dialogue throughout the health care system. Improving health outcomes and managing the high costs of specialty drugs. As only Prime can do it.
“Our health care system is not good at looking at the whole patient,” Sara said. “I’d like to help build that.”
January 18, 2022
The U.S. Food and Drug Administration (FDA) first approved Janssen Biotech’s Remicade® (infliximab)…
December 14, 2021
Rituxan® (rituximab) from Genentech was first approved by the FDA in 1997 for…
December 7, 2021
Herceptin® (trastuzumab) from Genentech is a targeted cancer drug used primarily to treat…